SK bioscience Initiates Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate

SK bioscience's first mRNA vaccine candidate enters Phase 1/2 clinical trials in Australia and New Zealand, with interim results expected by 2026 Joint R&D project between SK and CEPI includes up to USD 40 million in initial funding support from...